The second wave in kinase cancer drugs

Article Abstract:

The US Food and Drug Association (FDA) gave Onyx Pharmaceuticals approval of a protein kinase inhibitor for treating cancer and two more awaiting almost FDA approval with at least 40 in clinical trials makes kinase the second most popular drug target class in the pharmaceutical and biotech industries. The drugs, however, in most parts have neither met the expectations of the doctors who prescribed them nor the hopes of the patients who need them.

HEALTH SERVICES, Health care industry, Onyx Pharmaceuticals Inc., ONXX

---

Conflicting signals on US accelerated approvals

Article Abstract:

A study described that as London-based AstraZeneca disclosed results in December 2004 from phase 3 study showing its cancer drug Iressa did not produce a significant survival advantage over placebo, it has become the poster child for companies with accelerated approval whiplash. However, in June 2005, the pharmaceutical industry agreed to a label change that effectively nulls Iressa's approval.

Government regulation, Pharmaceutical industry, Licensing, certification and accreditation, Powers and duties, United States. Food and Drug Administration

---

Knockout drug screens

Article Abstract:

Researchers utilize a top-down drug screening strategy to show how compounds containing gene selective properties can be identified by isogenic cell lines that have a difference of just one genetic change.

Illustration

Similar abstracts:

• Abstracts: Chips advance but cost constraints remain. US patent office strategic plan may penalize biotechs. Racially defined haplotype project debated
• Abstracts: Sailing towards troubled waters. Changing Signals on the Kursk Lift. The Zumwalt-class destroyers
• Abstracts: Remaining relevant. Continental drift. Setting the tone
• Abstracts: The road to empowerment. Trusting your instincts. Sites for sore eyes
• Abstracts: Three back Centrica. Centrica. National Grid

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.